Becton Dickinson has entered 2026 after a significant $17.5 billion divestment of its Biosciences & Diagnostic Solutions business to Waters Corporation, positioning itself for operational efficiency. The company, which commands a 60% share of the U.S. infusion pump market, reported a stable adjusted operating margin of 25% and aims to maintain this floor in FY2026. While facing a projected revenue decline to $4.67 billion for the next quarter, it anticipates low single-digit growth moving forward and continues to uphold a strong dividend history, although analysts have recently lowered their price targets.
“Becton Dickinson · trades at · forward P/E · roughly 13x”
“Becton Dickinson · owns · U.S. infusion pump market · 60%”
“Becton Dickinson · generates · revenue from recurring consumables · over 90%”
“Becton Dickinson · posted · adjusted operating margin · 25%”
“Becton Dickinson · achieved · adjusted operating margin expansion · roughly 80 basis points per year”
“Becton Dickinson · held margin floor · FY2026 · 25%”
“Becton Dickinson · reduced its manufacturing footprint · global sites · from over 90 to fewer than 50”
“Becton Dickinson · launched · cost-out program · $200 million”
“Becton Dickinson · Q1 FY2026 total revenue · revenue · $5.25 billion”
“Becton Dickinson · targeted · annual drug delivery revenue by 2030 · $1 billion”
“Becton Dickinson · collected · Waters proceeds · $4 billion”
“Becton Dickinson · paid a penalty for misleading investors · about Alaris risks · $175 million”
